相关实验视频
Updated: Jun 28, 2025

10:37
Ferric Chloride-induced Murine Thrombosis Models
Published on: September 5, 2016
21.6K
选择性结合基质纤维素模仿奇托桑纳米颗粒的激活血小板和有效的药物释放用于抗血栓治疗
Yu Huang1, Jiahua Wang2, Yuanyuan Guo2
1Department of Radiology, Shanghai Jiao Tong University School of Medicine Affiliated Shanghai Sixth People's Hospital, 600 Yi Shan Road, Shanghai 200233, PR China; Department of Chemical Engineering, Imperial College London, South Kensington Campus, London SW7 2AZ, United Kingdom.
International journal of biological macromolecules
|April 23, 2024
概括
研究人员开发了一种新型纳米粒子,ASA-RGD-CS@TPP,用于有针对性的输送乙盐酸 (ASA). 这种仿生方法通过选择性向激活血小板来增强抗血小板治疗,提高安全性和疗效.
科学领域:
- 生物材料科学 生物材料科学
- 纳米技术纳米技术
- 药理学 药理学是指药理学的学科.
背景情况:
- 血栓形成导致严重的健康事件,如中风和心脏病发作.
- 乙盐酸 (ASA) 是一种抗血栓剂,但具有局限性,包括出血风险和耐药性.
- 目前的ASA疗法需要改进,以提高安全性和疗效.
研究的目的:
- 开发一个有针对性的纳米粒子系统,以改善ASA传递.
- 创建一个生物模拟平台,选择性地准激活血小板.
- 为了增强抗血栓疗效,同时最大限度地降低出血风险.
主要方法:
- 通过离子凝制造,制造模仿阴离子纤维素的纳米粒子 (ASA-RGD-CS@TPP).
- 使用素-甘氨酸-酸 (RGD) 移植的奇托 (RGD-CS) 和三聚酸 (TPP).
- 在小鼠模型中对血小板结合,ASA释放,抗血栓活性和生物相容性的体外和体内评估.
主要成果:
- ASA-RGD-CS@TPP纳米粒子选择性地与激活的血小板结合.
- 通过循环氧化酶-1 (COX-1) 阻断观察到ASA的有效释放和血小板聚合的强烈抑制.
- 这些纳米颗粒在体内显示出延长血液循环,有效预防血栓形成,与自由ASA相比降低出血风险.
结论:
- 开发的仿生纳米粒子系统为抗血栓治疗提供了安全,有效和有针对性的策略.
- ASA-RGD-CS@TPP通过改善ASA输送和减少副作用来增强抗血栓治疗.
- 这个平台代表了纳米医学的有希望的进步,用于管理血栓性疾病.
相关概念视频
Anticoagulant Drugs: Low-Molecular-Weight Heparins
687
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
687
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
522
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
522
Clot Retraction and Fibrinolysis
5.7K
After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
5.7K
Formation of the Platelet Plug
6.0K
The platelet phase, the second stage of hemostasis, commences around 15-20 seconds after an injury. It follows and overlaps with the vascular phase, during which blood vessels constrict to minimize blood loss.
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
6.0K

